---
$id: https://graph.org.ai/products/commodity/51131717
$type: Product
source: UNSPSC
code: "51131717"
title: "Dacopafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Dacopafant

**UNSPSC Code**: 51131717
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C12H11N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1T03Z1G60, chemically known as (3r)-3-(3-pyridyl)-1h,3h-pyrrolo(1,2-c)thiazole-7-carboxamide. but generally known as dacopafant, which bears US NIH Compound Identifier 205955. European Medicines Agency schedules Dacopafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06886MIG. The term DACOPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). DACOPAFANT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dacopafant under HS 29349990 and SITC 51579. As of Q4 2014, DACOPAFANT remains the US FDA Preferred Term for this commodity. Dacopafant bears US NLM identifiers UMLS ID C2348068 and NCI Concept Code C73132. SMILES: C1C2=C(C=CN2[C@H](S1)C3=CN=CC=C3)C(=O)N.

